首页> 外文OA文献 >Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study
【2h】

Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study

机译:Tariquidar和Elacridar的剂量依赖性通过P-糖蛋白和Bcrp在血脑屏障中转运:小动物正电子发射断层扫描和体外研究

摘要

Elacridar (ELC) and tariquidar (TQD) are generally thought to be nontransported inhibitors of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP), but recent data indicate that they may also be substrates of these multidrug transporters (MDTs). The present study was designed to investigate potential transport of ELC and TQD by MDTs at the blood-brain barrier at tracer doses as used in positron emission tomography (PET) studies. We performed PET scans with carbon-11-labeled ELC and TQD before and after MDT inhibition in wild-type and transporterknockout mice as well as in in vitro transport assays in MDToverexpressing cells. Brain entrance of [
机译:通常认为Elacridar(ELC)和tariquidar(TQD)是P-糖蛋白(Pgp)和乳腺癌抗性蛋白(BCRP)的非转运抑制剂,但最近的数据表明它们也可能是这些多药转运蛋白(MDT)的底物。本研究旨在研究在正电子发射断层扫描(PET)研究中使用的示踪剂量下,MDT在血脑屏障处通过MDT转运ELC和TQD的可能性。我们在野生型和转运敲除小鼠的MDT抑制前后,用碳11标记的ELC和TQD进行PET扫描,以及在MDT过表达细胞中进行体外转运测定。 [

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号